Clinical Trials Browser

Prostatic Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Prostatic Neoplasms

Prostatic Neoplasms

Prostate Adenocarcinoma

Breast Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Advanced Prostate Cancer

Breast Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Advanced Metastatic Breast Cancer

Prostatic Neoplasms

Breast Cancer Invasive

Prostatic Neoplasms

Prostatic Neoplasms, Sexual Dysfunction, Physiological

Breast Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Advanced Breast Cancer

Advanced Breast Cancer

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms, Osteitis Deformans

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Anemia, Osteoporosis, Prostatic Neoplasms, Hot Flashes

Prostatic Neoplasms

Prostatic Neoplasms

Clinical Trials

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Adjuvant WIDER

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

e3

CASPAR

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

AMEERA-5

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

CARLHA-2

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer

Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer

PCS III

A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer

Detect V / CHEVENDO (Chemo vs. Endo)

PATHWAY

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

MONALEESA-7

Study of Histrelin Subdermal Implant in Patients With Prostate Cancer

Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)

URONCOR 06-24

RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery

COMPLEEMENT-1

DART

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

SAFIA

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

ASPAIT

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity

LARES

Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer

PATCH

Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer